Vantage logo

Finding the next Vertex

Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.

Vantage logo

Gout flop leaves Sobi red-faced

SEL-212 fails to beat Krystexxa in phase II, but why did Sobi pay $100m for the asset in June and then put it into phase III?

Vantage logo

Horizon looks for a new growth driver

The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.